Alemtuzumab

From OncoWiki
Jump to: navigation, search

Drug information

Campath

Indications

Chronic lymphocytic leukemia

  • I.V. infusion: Initial: 3 mg/day beginning on day 1; if tolerated (infusion reaction ≤grade 2), increase to 10 mg/day; if tolerated (infusion reaction ≤grade 2), increase to maintenance of 30 mg/dose 3 times/week on alternate days for a total duration of therapy of up to 12 weeks
  • SubQ (unlabeled route): Initial: 3 mg on day 1; if tolerated 10 mg on day 3; if tolerated increase to 30 mg on day 5; maintenance: 30 mg/dose 3 times/week for a maximum of 18 weeks (Lundin, 2002) or 3 mg on day 1; if tolerated 10 mg on day 2; if tolerated 30 mg on day 3, followed by 30 mg/dose 3 times/week for 4-12 weeks (Stilgenbauer, 2009)
  • Bactrim DS 1 tab po bid tiw
  • Famciclovir 250 mg po bid

References